Press Releases
Heineken® says cheers to the Real Hardcore Fans as thousands of fans faces adorn the celebration confetti during the UEFA Champions League Final 2024 Trophy Lift at Wembley
LONDON, June 01, 2024 (GLOBE NEWSWIRE) -- Tonight, Heineken® has created a way for thousands of ‘real hardcore fans’ to take part in the UEFA Champions League Final Trophy celebration, marking the culmination of the ‘Cheers To The Real Hardcore Fans’ 2024 campaign.
Following... (continue reading...)
SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, presented the Phase 1 clinical data of its first-in-class PD-1/IL-2α bispecific antibody fusion protein (R&D code: IBI363) in advanced solid... (continue reading...)
SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1... (continue reading...)
SAN FRANCISCO, U.S. and SUZHOU, China , June 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented Phase 1 clinical data of IBI343 (TOPOi anti-CLDN18.2 ADC) for the treatment of advanced pancreatic ductal... (continue reading...)
SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cetuximab for first-line non-small cell lung cancer (NSCLC) treatment,at the 2024 American Society of Clinical Oncology (ASCO) annual meeting.
The preliminary result of the... (continue reading...)
More Press Releases
View Older Stories-
Quebec Precious Metals Announces First Closing of a Private Placement
-
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
-
Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
-
National Skills Champions are Honoured at the Skills Canada National Competition 2024, in Québec
-
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
-
BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025
-
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
-
First Federal Savings Bank and ICBA Offer Tips to Help Simplify the Homebuying Process
-
Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy
-
Sun, Sand, and Smooth Skin: Grab Ulike Air 10 for a Summer Beach Adventure
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
-
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
-
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Upd
-
Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
-
All-in-One Job Shop Software for Fabrication Shops by Steelhead Technologies
-
Sustainable Tourism Initiative: Responsible Travel Merchandise Store Announced
-
What Custom Stickers Are Best for Glass?
-
Robotbulls - The Future of Cryptocurrency Trading: Integrating AI and Blockchain Data
-
Taseko Announces that Operations at its Gibraltar Mine have been Suspended
-
Michael Bernstein Offers Dropshipping Consulting to Help Clients Build Successful, Long-Term Businesses
-
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
-
PHILADELPHIA KICKS OFF PRIDE MONTH BY SETTING THE FIRST-EVER GUINNESS WORLD RECORDS™ FOR THE "LARGEST ATTENDANCE AT DRAG QUEEN STORY TIME"
-
Union members and allies mark Injured Workers’ Day in locations across Ontario
-
FameEX CEO’s Message: Keep the Intention in the Crypto Bull Market for a Better Departure
-
Prospera Energy Inc. Announces 2023 Financial Results
-
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!
-
WATCH by Aisles: A Revolutionary AI System for Public Safety
-
CIO Women Magazine Spotlights Claudia Patricia Eusse, CEO, The Eusse Group, as Influential Women Leaders in Real Estate
-
Mr. Business Magazine Spotlights Diana Muniz-Lebrun, Founding Partner and CEO at Olympus Marketing
-
ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
-
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
-
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
-
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
-
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
-
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-sma
-
Gregory P Lee Personal Injury Lawyer The Woodlands Expands Services to Meet Rising Demand in Texas for Personal Injury Cases
-
Innovative Solutions and Cutting-Edge Technologies Take Centre Stage at Water Expo Delhi 2024
-
Revolutionizing Sustainability: The Environment Protection Technologies Expo
-
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Flash News: OKX Announces Position Tier Adjustments for TURBO/USDT Perpetual Futures Listing
-
Fungies Mushroom Gummies Announces Major Retail Expansion and Availability at Walmart
-
Vincent Todd Announces the Introduction of Todd Agriscience
-
Hyundai Motor America Reports May 2024 Sales
-
Beverly Hills MD Celebrates Its 10th Anniversary
-
American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors